|
BP13778
|
CPI-637
|
|
|
|
|
CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor.
|
|
BP13777
|
CPI-455
|
|
|
|
|
CPI-455 is a specific KDM5 inhibitor.
|
|
BP13776
|
CPI-455 HCl
|
|
|
|
|
CPI-455 is a specific KDM5 inhibitor with IC50 value of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with targeted agents or standard chemotherapy.
|
|
BP13775
|
CPI203
|
|
|
|
|
CPI-203 is an effective BET bromodomain inhibitor (IC50: 37 nM for BRD4).
|
|
BP13774
|
CPI-203
|
|
|
|
|
CPI-203 is an effective BET bromodomain inhibitor (IC50: 37 nM for BRD4).
|
|
BP13773
|
CPI-169 racemate
|
|
|
|
|
CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
|
|
BP13772
|
CPI-1205
|
|
|
|
|
CPI-1205 is a highly potent and selective inhibitor of EZH2(IC50 : 0.002 μM, EC50 : 0.032 μM).
|
|
BP13771
|
CPI-0610 carboxylic acid
|
|
|
|
|
CPI-0610 carboxylic acid is a ligand for target protein for PROTAC. It is a potent bromodomain and extra-terminal (BET) protein inhibitor with the potential in the therapy of multiple myeloma.
|
|
BP13770
|
CP21R7
|
|
|
|
|
CP21R7 is an effective and specific GSK3β inhibitor. It is used as an activator of stem cells prior to the induction of differentiation of stem cells to smooth muscle and endothelial cells. CP21R7 can be combined with BMP4 to commit human pluripotent stem cells to a mesodermal fate.
|
|
BP13769
|
Aldometanib
|
|
|
|
|
Compound IA-47 activates AMPK activity in the liver and reduces triglyceride levels by inhibiting aldolase activity. Compound IA-47 can be used in studies about preventing and treating obesity and diabetes.
|
|
BP13768
|
CM-579 trihydrochloride (1846570-40-8 free base)
|
|
|
|
|
CM-579 trihydrochloride is a first-in-class reversible and dual inhibitor of G9a and DNMT (IC50s: 16 nM, 32 nM) with potent in vitro cellular activity in a wide range of cancer cells.
|
|
BP13767
|
CM-579
|
|
|
|
|
CM-579 is a dual inhibitor of G9a and DNMT( IC50:16 nM, 32 nM for G9a and DNMT). It has potent in vitro cellular activity in a wide range of cancer cells.
|
|
BP13766
|
Clitorin
|
|
|
|
|
Clitorin has free radical scavenging property. It shows significant interactions with CD38, it may have anti-hyperglycemic potential.
|
|
BP13765
|
Cimiracemoside C
|
|
|
|
|
Cimiracemoside C is an active component of Cimicifuga racemosa. It activates AMPK and has the potential activity against diabetes.
|
|
BP13764
|
Cholesteryl sulfate sodium
|
|
|
|
|
Cholesterol sulfate is a sterol sulfate in human plasma. It is a component of cell membrane and has a regulatory function. It also activates multiple protein kinase C (PKC) iso-enzymes, especially the ε, η and ζ isoforms.
|
|
BP13763
|
Chlorogenic Acid
|
|
|
|
|
Chlorogenic acid is a naturally occurring phenolic acid which is a carcinogenic inhibitor. It has also been shown to prevent paraquat-induced oxidative stress in rats.
|
|
BP13762
|
Chitosan oligosaccharide
|
|
|
|
|
Chitosan oligosaccharide, an oligomer of β-(1→4)-linked D-glucosamine, activates AMPK and inhibits inflammatory signaling pathways.
|
|
BP13761
|
Chikusetsusaponin IVa
|
|
|
|
|
Chikusetsusaponin IVa is a novel AMPK activator, can induce insulin secretion from βTC3 cells via GPR4 mediated calcium and PKC pathways, may be developed into a new potential for therapeutic agent used in T2DM patients.
|
|
BP13760
|
CHEMBRDG-BB 7118966
|
|
|
|
|
CHEMBRDG-BB 7118966 is an inhibitor of Bromodomain-containing protein 4 (human).
|
|
BP13759
|
CHDI-390576
|
|
|
|
|
CHDI-390576 is a CNS penetrant class IIa HDAC inhibitor (IC50s: 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9). It shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform.
|
.gif)
